Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation (Q33231452)

24 July 2017

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation (English)

1 reference

24 July 2017

1 reference

9

Ravi Salgia

1 reference

24 July 2017

3

Tanguy Y Seiwert

1 reference

24 July 2017

8

Aliya N Husain

1 reference

24 July 2017

Nicholas W Choong

1

1 reference

24 July 2017

Sascha Dietrich

2

1 reference

24 July 2017

Maria S Tretiakova

4

1 reference

24 July 2017

Vidya Nallasura

5

1 reference

24 July 2017

Gareth C Davies

6

1 reference

24 July 2017

Stanley Lipkowitz

7

1 reference

24 July 2017

Patrick C Ma

10

1 reference

24 July 2017

1 January 2006

1 reference

Nature Clinical Practice Oncology

24 July 2017

1 reference

24 July 2017

3

1 reference

24 July 2017

50-7; quiz 1 p following 57

1 reference

24 July 2017

1

1 reference

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

24 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Leptomeningeal carcinomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Neoplastic Meningitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Leptomeningeal metastasis: survival and prognostic factors in 155 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0400

7 January 2021

Identifiers

DOI

10.1038/NCPONC0400

1 reference

24 July 2017

1 reference